Pacific Biosciences of California Inc
NASDAQ:PACB
Intrinsic Value
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. [ Read More ]
The intrinsic value of one
PACB
stock under the Base Case scenario is
4.82
USD.
Compared to the current market price of 1.31 USD,
Pacific Biosciences of California Inc
is
Undervalued by 73%.
PACB's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PACB or that its price is influenced by factors unrelated to fundamentals.
Pacific Biosciences of California Inc's market capitalization is 350.7m USD.
PACB stock price is 1.31 USD.
PACB stock price (1.31 USD) is 73% less than its Intrinsic Value (4.82 USD).
PACB. Open DCF Valuation
PACB has upside potential of 364% compared to the average analyst price target.
Open Wall St Estimates
PACB's D/E (Debt to Equity) is equal to 1.27.
PACB's ROE (Return on Equity) has significantly decreased in the last 3 years from -35% to -49%, and is approaching profitability.
PACB has negative Net Debt. This means that the company has more cash and short-term investments (1B USD) than debt (892m USD).
PACB's long-term assets (2B USD) exceed its long-term liabilties (1B USD).
PACB's Revenue has grown by an exceptional 56% over the past 12 months.
PACB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -119% to -38%, and is approaching profitability.
PACB's Revenue is forecast to grow at a rate of 35% per year over the next 3 years.
PACB has positive Gross Profit for the last twelve months.
PACB has negative Operating Income for the last twelve months.
PACB has negative Net Income for the last twelve months.
PACB's ROE (Return on Equity) for the past 12 months is negative and is equal to -49%.
PACB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -38%.
PACB's Revenue has been growing by an exceptional 36% per year for the last 3 years.
PACB has negative Free Cash Flow for the last twelve months.
PACB has negative three-year average ROE (Return on Equity): -36%. The company is not efficient at transforming stockholders' equity into net income.
PACB has negative three-year average ROIC (Return on Invested Capital): -52%. The company is not efficient at using invested capital to generate operating income.
PACB's short-term assets (742m USD) exceed its short-term liabilties (95m USD).
PACB's Altman Z-Score is very low and is equal to -0.76.
PACB doesn't generate enough operating income (-322m USD) to safely cover interest payments on its debt (16m USD).
Valuation Backtest
Pacific Biosciences of California Inc
Run backtest to discover the historical profit from buying and selling
PACB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Pacific Biosciences of California Inc
Balance Sheet Decomposition
Pacific Biosciences of California Inc
| Current Assets | 742m |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 36.6m |
| Other Current Assets | -377.5m |
| Non-Current Assets | 1B |
| PP&E | 69m |
| Intangibles | 919.2m |
| Other Non-Current Assets | 15.7m |
| Current Liabilities | 95m |
| Accounts Payable | 15.1m |
| Accrued Liabilities | 55.3m |
| Other Current Liabilities | 24.7m |
| Non-Current Liabilities | 949.7m |
| Long-Term Debt | 892.2m |
| Other Non-Current Liabilities | 57.4m |
Earnings Waterfall
Pacific Biosciences of California Inc
|
Revenue
|
200.5m
USD
|
|
Cost of Revenue
|
-144.3m
USD
|
|
Gross Profit
|
56.2m
USD
|
|
Operating Expenses
|
-378.2m
USD
|
|
Operating Income
|
-322m
USD
|
|
Other Expenses
|
15.3m
USD
|
|
Net Income
|
-306.7m
USD
|
Free Cash Flow Analysis
Pacific Biosciences of California Inc
PACB Profitability Score
Profitability Due Diligence
Pacific Biosciences of California Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Pacific Biosciences of California Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
PACB Solvency Score
Solvency Due Diligence
Pacific Biosciences of California Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Pacific Biosciences of California Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PACB Price Targets Summary
Pacific Biosciences of California Inc
According to Wall Street analysts, the average 1-year price target for
PACB
is 6.08 USD
.
Ownership
PACB Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PACB Price
Pacific Biosciences of California Inc
| Average Annual Return | 74.64% |
| Standard Deviation of Annual Returns | 225.09% |
| Max Drawdown | -97% |
| Market Capitalization | 350.7m USD |
| Shares Outstanding | 267 952 000 |
| Percentage of Shares Shorted | 20.29% |
Company Profile
Pacific Biosciences of California Inc
Country
Industry
Market Cap
Dividend Yield
Description
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 728 full-time employees. The company went IPO on 2010-10-27. The firm designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The firm has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include Sequel, Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together can sequence up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together conduct, monitor, and analyze single molecule biochemical reactions in real time. The firm's Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.
Contact
IPO
Employees
Officers
The intrinsic value of one
PACB
stock under the Base Case scenario is
4.82
USD.
Compared to the current market price of 1.31 USD,
Pacific Biosciences of California Inc
is
Undervalued by 73%.
You don't have any saved screeners yet
